Helen Giza of FME is excited about the possibilities new drugs such as Ozempic could offer for renal patients

New popular weight-loss drugs such as Wegovy and Ozempic come with an additional benefit: they could prolong the life of people with chronic kidney disease, says Helen Giza.

For Giza, who runs the world’s largest dialysis and renal services company, Fresenius Medical Care (FME), and for the patients it serves, the new breed of weight-loss jabs promises to be transformational.